Brief: TCR² Therapeutics Reports Q4 Loss Per Share $0.55
11/03/2021 12:07
March 11 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2020
FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* PRELIMINARY SAFETY, EFFICACY AND TRANSLATIONAL DATA FROM
GAVO-CEL PHASE 1 TRIAL AT AACR 2021
* PRECLINICAL DATA ON AUTOLOGOUS CD70 AND ALLOGENEIC
MESOTHELIN
TRUC DATA AT AACR 2021
* QTRLY LOSS PER SHARE $0.55
* Q4 EARNINGS PER SHARE VIEW $-0.56 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX854fX0
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview